Kamada (KMDA) Soars 8.1%: Is Further Upside Left in the Stock?

Kamada (KMDA) shares rallied 8.1% in the last trading session to close at $8.56. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 12% gain over the past four weeks.

Kamada’s stock price increase reflects increasing investor confidence following the company’s robust 2026 guidance, which forecasts sustained double-digit, profitable growth driven entirely by organic expansion of existing products across proprietary and distribution portfolios. Furthermore, management’s expectation to surpass 2025 revenue guidance, supported by strong profitability and an estimated positive year-end cash balance, has further alleviated near-term execution risk.

This biopharmaceutical is expected to post quarterly earnings of $0.09 per share in its upcoming report, which represents a year-over-year change of +28.6%. Revenues are expected to be $45.73 million, up 17.2% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Kamada, the consensus EPS estimate for the quarter has been revised 3% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on KMDA going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Kamada is part of the Zacks Medical - Biomedical and Genetics industry. PTC Therapeutics (PTCT), another stock in the same industry, closed the last trading session 1.3% higher at $76.23. PTCT has returned -4.2% in the past month.

For PTC Therapeutics, the consensus EPS estimate for the upcoming report has changed +12.9% over the past month to -$0.37. This represents a change of -54.2% from what the company reported a year ago. PTC Therapeutics currently has a Zacks Rank of #3 (Hold).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research